

## SCIENTIFIC PROGRAMME

Wednesday 10th June 2009

09.00 – 10.45

### **SESSION 4: Genes to drugs**

Chair: Ian Collins  
The Institute of Cancer Research

09.00 – 09.35

### **Zen and the art of genome maintenance: from Ku to KuDOS**

Steve Jackson  
Wellcome Trust/Cancer Research UK Gurdon Institute,  
Cambridge

09.35 – 10.10

### **Bcl-2 family inhibitors for the treatment of cancer**

Stephen Fesik  
Abbott, Abbott Park, USA

10.10 – 10.45

### **BRAF in human cancer: biology and therapeutics**

Richard Marais  
The Institute of Cancer Research

10.45 – 11.15

### **COFFEE**

11.15 – 13.00

### **SESSION 4: Genes to drugs (continued)**

Chair: Caroline Springer  
The Institute of Cancer Research

11.15 – 11.50

### **Feedback and redundancy in oncoprotein-activated signalling pathways - basic and therapeutic implications**

Neal Rosen  
Memorial Sloan-Kettering Cancer Center, New York, USA

11.50 – 12.25

### **Overcoming resistance to molecularly targeted therapy**

Charles Sawyers  
Memorial Sloan-Kettering Cancer Center, New York, USA

12.25 – 13.00

### **Accelerating anticancer drug development by rational trial design**

Johann de Bono  
The Institute of Cancer Research

13.00 – 14.30

**LUNCH and POSTER SESSION**

14.30 – 16.15

**SESSION 4: Genes to drugs (continued)**

Chair: Stan Kaye  
The Institute of Cancer Research

14.30 – 15.05

**Limited drug distribution and repopulation in solid tumours as important and neglected causes of resistance to chemotherapy**

Ian Tannock  
Ontario Cancer Institute, Toronto, Canada

15.05 – 15.40

**Targeting PI3 kinase in the clinic**

José Baselga  
Val D'Hebron University Hospital, Barcelona, Spain

15.40 – 16.15

**Drugging the cancer genome: towards personalised molecular medicine**

Paul Workman  
The Institute of Cancer Research

16.15 – 16.30

**Closing remarks**

Peter Rigby  
The Institute of Cancer Research